Pfizer settles patent litigation regarding Teva's generic Neurontin

05/31/2011 | Bloomberg

Pfizer reached a settlement with Teva Pharmaceutical Industries that lets the latter continue marketing a generic version of epilepsy medicine Neurontin. Pfizer had said generic Neurontin sold by Teva and its unit Ivax, as well as Actavis Group subsidiary Purepac, infringes a key patent that lasts until 2017.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ